Checkmate Pharmaceuticals

General Information


We are a clinical-stage biotechnology company focused on developing and commercializing our proprietary technology to harness the power of the immune system to combat cancer. Our product candidate, CMP-001, is a differentiated Toll-like receptor 9, or TLR9, agonist delivered as a biologic virus-like particle, or VLP, utilizing a CpG-A oligonucleotide as a key component. When injected into a tumor, CMP-001 is designed to trigger the body’s innate immune system, thereby altering the tumor microenvironment and directing activated anti-tumor T cells to attack both the injected tumor and also tumors throughout the body.

Employees: 22
Founded: 2015
Contact Information
Address 245 Main Street, 2nd Floor, Cambridge, MA 02142, US
Phone Number (617) 682-3625
Web Address
View Prospectus: Checkmate Pharmaceuticals
Financial Information
Market Cap $321.6mil
Revenues $0 mil (last 12 months)
Net Income $-36.2 mil (last 12 months)
IPO Profile
Symbol CMPI
Exchange NASDAQ
Shares (millions): 5.0
Price range $15.00 - $15.00
Est. $ Volume $75.0 mil
Manager / Joint Managers BofA Securities/ Jefferies/ BMO Capital Markets
CO-Managers BTIG
Expected To Trade: 8/7/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change